<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="other"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Gas Res</journal-id><journal-id journal-id-type="publisher-id">MGR</journal-id><journal-id journal-id-type="publisher-id">Med Gas Res</journal-id><journal-title-group><journal-title>Medical Gas Research</journal-title></journal-title-group><issn pub-type="epub">2045-9912</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC466993</article-id><article-id pub-id-type="publisher-id">MGR-14-149</article-id><article-id pub-id-type="doi">10.4103/2045-9912.390249</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Hydrogen inhalation therapy may ameliorate amyotrophic lateral sclerosis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ichikawa</surname><given-names>Yusuke</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2526-4681</contrib-id><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Sato</surname><given-names>Bunpei</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Hirano</surname><given-names>Shin-ichi</given-names></name><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8610-8922</contrib-id><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Takefuji</surname><given-names>Yoshiyasu</given-names></name><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1826-742X</contrib-id><xref rid="aff3" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Satoh</surname><given-names>Fumitake</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Research and Development Department, MiZ Company Limited, Kamakura, Kanagawa, Japan</aff><aff id="aff2">MiZ Inc., Balentine Drive, Newark, CA, USA</aff><aff id="aff3">Faculty of Data Science, Musashino University, Tokyo, Japan; Keio University, Tokyo, Japan</aff><author-notes><corresp id="cor1"><label>*</label><italic toggle="yes"><bold>Correspondence to:</bold> Yusuke Ichikawa, <email xlink:href="y_ichikawa@e-miz.co.jp">y_ichikawa@e-miz.co.jp</email></italic>.</corresp></author-notes><pub-date pub-type="collection"><season>Jul-Sep</season><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>3</month><year>2024</year></pub-date><volume>14</volume><issue>3</issue><fpage>149</fpage><lpage>150</lpage><history><date date-type="received"><day>07</day><month>2</month><year>2023</year></date><date date-type="rev-recd"><day>10</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2024 Medical Gas Research</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions></article-meta></front><body><p>Amyotrophic lateral sclerosis (ALS) is a motor neuron disease, a neurodegenerative disorder characterized by sporadic and progressive degenerative loss of cell bodies of both the upper and lower motor neurons.<xref rid="R1" ref-type="bibr">1</xref><xref rid="R2" ref-type="bibr">2</xref> Clinical manifestations of ALS are known to include lower motor neuron symptoms, upper motor neuron symptoms, bulboparesthesia symptoms, cognitive dysfunction, and negative signs.<xref rid="R3" ref-type="bibr">3</xref> Dissociated small hand atrophy is also known as a characteristic symptom.<xref rid="R4" ref-type="bibr">4</xref> ALS is always progressive, and once a person has the disease, there is no relief from the symptoms.<xref rid="R5" ref-type="bibr">5</xref> No matter which part of the body the symptoms start in, eventually all the muscles in the body are affected, and finally the respiratory muscles also stop working, with a majority of people suffering from respiratory failure.<xref rid="R6" ref-type="bibr">6</xref> Without the use of a ventilator, the time from illness to death is roughly 3&#x02013;5 years.<xref rid="R5" ref-type="bibr">5</xref><xref rid="R6" ref-type="bibr">6</xref> Since reactive oxygen species are known to be closely related to the onset of ALS, antioxidants are expected to contribute to the suppression of ALS onset and improvement of its symptoms, and a number of antioxidants have been developed as candidates for ALS treatment.<xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref> However, all of these antioxidants have been used only as a coping strategy, and there is no antioxidant that has been found to fundamentally improve ALS.<xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref></p><p>It has been proposed that molecular hydrogen may inhibit chronic inflammation by scavenging hydroxyl radicals generated within cells and mitochondria, which may have an effect on many diseases caused by chronic inflammation.<xref rid="R9" ref-type="bibr">9</xref><xref rid="R10" ref-type="bibr">10</xref><xref rid="R11" ref-type="bibr">11</xref> However, there are no reports of prevention or amelioration of ALS or ALS-related symptoms.</p><p>This perspective describes the mechanism of action in the development of ALS, touches on the possibility of ALS amelioration by hydrogen, and presents a case in which ALS symptoms were ameliorated by inhalation of hydrogen gas.</p><p><bold>Mechanism of ALS pathogenesis:</bold> Based on the mechanism of oxygen-induced damage, the pathogenesis of ALS can be explained. It is the excessive deposition of metal ions in the brain, rather than the lack of metal ions, that is the problem in the association between neurological disease and abnormal metal metabolism. In ALS patients, the first motor cortex of the cerebral cortex is also prone to excessive deposition of metal ions such as iron ions (<bold><xref rid="F1" ref-type="fig">Figure 1</xref></bold>).<xref rid="R12" ref-type="bibr">12</xref><xref rid="R13" ref-type="bibr">13</xref> Trivalent iron ions (Fe<sup>3+</sup>) deposited into the brain are absorbed into upper motor neurons by transferrin receptor 1 and reduced to divalent iron (Fe<sup>2+</sup>) by divalent metal transporters (<bold><xref rid="F1" ref-type="fig">Figure 1</xref></bold>).<xref rid="R14" ref-type="bibr">14</xref> On the other hand, leakage of electrons in the electron transfer system occurs inside mitochondria, which are known to produce the highest amount of reactive oxygen species in the cell, and 1&#x02013;5% of the oxygen used for respiration is converted to hydrogen peroxide via superoxide.<xref rid="R15" ref-type="bibr">15</xref> Hydrogen peroxide produces hydroxyl radicals (Fenton reaction) by one-electron reduction, in which hydrogen peroxide receives an electron from the reducing Fe<sup>2+</sup>.<xref rid="R10" ref-type="bibr">10</xref><xref rid="R11" ref-type="bibr">11</xref><xref rid="R16" ref-type="bibr">16</xref> Hydroxyl radicals have the strongest oxidative activity and indiscriminately attack neurons in the brain, destroying neurons and cellular constituents, resulting in ALS.<xref rid="R11" ref-type="bibr">11</xref> These are the so-called mechanisms of ferroptosis. Therefore, the key to preventing and improving ALS is how to eliminate hydroxyl radicals generated in the brain.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Mechanism of cell damage by ferroptosis.</p><p>Note: Hydroxyl radicals are generated by the Fenton reaction in the brain of healthy people. However, in the first motor cortex of the brain of ALS patients, metal ions such as iron ions are easily deposited. Metal ions deposited in the brain accelerate the Fenton reaction and generate more hydroxyl radicals, causing damage to cranial nerve cells (ferroptosis), which is thought to be a major factor in the pathogenesis of ALS. Therefore, how to eliminate hydroxyl radicals generated in the brain is an important issue for the prevention and improvement of ALS. Created with Microsoft PowerPoint 2019 MSO. ALS: Amyotrophic lateral sclerosis.</p></caption><graphic xlink:href="MGR-14-149-g001" position="float"/></fig><p><bold>Role of hydrogen in the living body:</bold> Hydrogen is the smallest diatomic molecule and can freely penetrate cell membranes to reach the brain.<xref rid="R16" ref-type="bibr">16</xref> Hydrogen can also react with hydroxyl radicals and protect the brain from hydroxyl radical attack by converting hydroxyl radicals to water molecules.<xref rid="R16" ref-type="bibr">16</xref> Given the mechanism of action of ALS, it is thought that the progression of ALS can be inhibited and improved if antioxidants can be delivered to the areas of the brain where metals are deposited and hydroxyl radicals can be scavenged; however, attempts to use antioxidants have failed.<xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref> For example, edaravone, a radical scavenger known as a therapeutic agent for ALS, has a large molecular weight, making it difficult for it to reach deep into the brain. There is also a limit to how much of the reaction byproduct of edaravone can be expelled from the brain, and it is associated with serious side effects. Therefore, edaravone cannot stop the progression of ALS.<xref rid="R12" ref-type="bibr">12</xref><xref rid="R17" ref-type="bibr">17</xref> In addition to edaravone, other drugs targeting cranial nerve diseases face the following problems.</p><list list-type="bullet"><list-item><p>Problem 1: Must penetrate the blood-brain barrier.</p></list-item><list-item><p>Problem 2: Must target the affected part of the brain. It is particularly difficult to reach the deep brain. It is also difficult to penetrate intracellular organelles such as mitochondria.</p></list-item><list-item><p>Problem 3: Metabolites must be removed from the brain to the outside of the brain.</p></list-item><list-item><p>Problem 4: The drug itself has side effects.</p><p>On the other hand, hydrogen, unlike other antioxidants, has the following advantages.</p></list-item><list-item><p>Advantage 1: It is an inert substance and does not react with biological substances other than hydroxyl radicals</p></list-item><list-item><p>Advantage 2: Because it is a diatomic molecule at minimum, it can penetrate cell membranes and reach deep into the brain. Furthermore, it can not only enter the cytoplasm, but also reach the inside of cell organelles such as mitochondria and nucleus, and can scavenge hydroxyl radicals generated inside intracellular organelles.</p></list-item><list-item><p>Advantage 3: Since the reaction product is a water molecule, there are no side effects caused by pharmaceutical byproducts.</p></list-item><list-item><p>Advantage 4: Excess hydrogen is naturally released from the body by diffusion.</p></list-item></list><p>Hydrogen can protect the brain with these advantages without any side effects. Hydrogen can easily overcome all the problems of pharmaceuticals. Because of this mechanism of action, hydrogen may be effective against neurological diseases such as ALS and Parkinson&#x02019;s disease, and we decided to confirm the effect of hydrogen on ALS symptoms by recommending one patient with ALS to inhale hydrogen gas. Care must be taken when handling hydrogen because it is explosive, so hydrogen gas inhalers that produce less than 10 volume hydrogen, which is under the explosive concentration, should be used.<xref rid="R18" ref-type="bibr">18</xref><xref rid="R19" ref-type="bibr">19</xref></p><p><bold>Case of ALS improvement by hydrogen gas inhalation:</bold> A 64-year-old Japanese man felt something wrong with his left calf in the spring of 2021, and when he went to the hospital in August of the same year, he was diagnosed with ALS. Doctors declared that there was no treatment for ALS and that he had 3 to 4 years to live. The paralysis in his left leg progressed, and the calf of his left leg became noticeably thinner than his right leg, which could be seen just by looking at it. Walking became difficult, and he could not walk straight without the use of a cane. The patient began inhaling hydrogen gas in October 2022. The hydrogen gas inhaler used was a product named Jobs-&#x003b1; (trademark registered as Jobs) from MiZ Company Limited (Kamakura, Kanagawa, Japan). The hydrogen concentration of Jobs-&#x003b1; is 4% to 5% and the hydrogen volume is 200 mL/min as 100% hydrogen generates. The inhalation time was 7 to 8 hours per day, mainly during sleep. On November 10, 2022, muscle tone in the left calf returned at a visually noticeable level. In early December 2022, the patient went on a business trip to Europe. His family was concerned about whether he could go on a business trip with his ALS, but he decided to go on the trip because his health condition had not deteriorated and he had been able to work energetically despite his difficult schedule due to inhalation of hydrogen gas. He had no problems walking, despite the cold weather and cool temperatures in Europe. Although he still uses a cane for safety, he has seen a definite improvement in his ability to walk. Other positive results include increased appetite and good bowel movements, and he has seen improvements in his blood pressure, blood sugar, and liver function. The study has obtained written informed consent from the patient.</p><p><bold>Conclusion:</bold> In view of the mechanism of conversion of hydroxyl radicals to water molecules by hydrogen as described above, hydrogen may have the potential to prevent ferroptosis in motor neurons, thereby inhibiting ALS progression. In this study, we succeeded in suppressing the paralysis and degeneration of the calf muscles, a symptom of ALS, and even improved the difficulty in walking by having one ALS patient actually inhale hydrogen. Until now, no drug has been able to halt the progression of ALS symptoms, and the disease has been so intractable that patients have had no choice but to wait for death. Although this is only one case, future clinical trials with multiple patients should confirm the effectiveness of this treatment.</p><p><italic toggle="yes">The authors are grateful to Ms. Yoko Satoh (MiZ Company Limited) for her excellent advice in the writing of this manuscript</italic>.</p><p><italic toggle="yes">YI, BS, SH, and FS are employees of MiZ Company limited</italic>.</p></body><back><ref-list><title>R<sc>EFERENCES</sc></title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cleveland</surname><given-names>DW</given-names></name>
<name><surname>Rothstein</surname><given-names>JD</given-names></name></person-group><article-title>From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS</article-title><source>Nat Rev Neurosci</source><year>2001</year><volume>2</volume><fpage>806</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">11715057</pub-id>
</element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bruijn</surname><given-names>LI</given-names></name>
<name><surname>Miller</surname><given-names>TM</given-names></name>
<name><surname>Cleveland</surname><given-names>DW</given-names></name></person-group><article-title>Unraveling the mechanisms involved in motor neuron degeneration in ALS</article-title><source>Annu Rev Neurosci</source><year>2004</year><volume>27</volume><fpage>723</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">15217349</pub-id>
</element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><collab>EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis</collab><person-group person-group-type="author">
<name><surname>Andersen</surname><given-names>PM</given-names></name>
<name><surname>Abrahams</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)- -revised report of an EFNS task force</article-title><source>Eur J Neurol</source><year>2012</year><volume>19</volume><fpage>360</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">21914052</pub-id>
</element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilbourn</surname><given-names>AJ</given-names></name></person-group><article-title>The &#x0201c;split hand syndrome&#x0201d;</article-title><source>Muscle Nerve</source><year>2000</year><volume>23</volume><fpage>138</fpage></element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bensimon</surname><given-names>G</given-names></name>
<name><surname>Lacomblez</surname><given-names>L</given-names></name>
<name><surname>Meininger</surname><given-names>V</given-names></name></person-group><article-title>A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group</article-title><source>N Engl J Med</source><year>1994</year><volume>330</volume><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">8302340</pub-id>
</element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Masrori</surname><given-names>P</given-names></name>
<name><surname>Van Damme</surname><given-names>P</given-names></name></person-group><article-title>Amyotrophic lateral sclerosis: a clinical review</article-title><source>Eur J Neurol</source><year>2020</year><volume>27</volume><fpage>1918</fpage><lpage>1929</lpage><pub-id pub-id-type="pmid">32526057</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Apostolski</surname><given-names>S</given-names></name>
<name><surname>Marinkovi&#x00107;</surname><given-names>Z</given-names></name>
<name><surname>Nikoli&#x00107;</surname><given-names>A</given-names></name>
<name><surname>Blagojevi&#x00107;</surname><given-names>D</given-names></name>
<name><surname>Spasi&#x00107;</surname><given-names>MB</given-names></name>
<name><surname>Mi-chelson</surname><given-names>AM</given-names></name></person-group><article-title>Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation</article-title><source>J Environ Pathol Toxicol Oncol</source><year>1998</year><volume>17</volume><fpage>325</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">9726810</pub-id>
</element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Desnuelle</surname><given-names>C</given-names></name>
<name><surname>Dib</surname><given-names>M</given-names></name>
<name><surname>Garrel</surname><given-names>C</given-names></name>
<name><surname>Favier</surname><given-names>A</given-names></name></person-group><article-title>A double-blind, placebocontrolled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group</article-title><source>Amyotroph Lateral Scler Other Motor Neuron Disord</source><year>2001</year><volume>2</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">11465936</pub-id>
</element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yanagihara</surname><given-names>T</given-names></name>
<name><surname>Arai</surname><given-names>K</given-names></name>
<name><surname>Miyamae</surname><given-names>K</given-names></name>
<etal/></person-group><article-title>Electrolyzed hydrogen-saturated water for drinking use elicits an antioxidative effect: a feeding test with rats</article-title><source>Biosci Biotechnol Biochem</source><year>2005</year><volume>69</volume><fpage>1985</fpage><lpage>1987</lpage><pub-id pub-id-type="pmid">16244454</pub-id>
</element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirano</surname><given-names>S-i</given-names></name>
<name><surname>Ichikawa</surname><given-names>Y</given-names></name>
<name><surname>Sato</surname><given-names>B</given-names></name>
<name><surname>Satoh</surname><given-names>F</given-names></name>
<name><surname>Takefuji</surname><given-names>Y</given-names></name></person-group><article-title>Hydrogen is promising for medical applications</article-title><source>Clean Technol</source><year>2020</year><volume>2</volume><fpage>529</fpage><lpage>541</lpage></element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirano</surname><given-names>SI</given-names></name>
<name><surname>Ichikawa</surname><given-names>Y</given-names></name>
<name><surname>Sato</surname><given-names>B</given-names></name>
<name><surname>Takefuji</surname><given-names>Y</given-names></name>
<name><surname>Satoh</surname><given-names>F</given-names></name></person-group><article-title>Molecular hydrogen as a medical gas for the treatment of myalgic encephalomyelitis/ chronic fatigue syndrome: possible efficacy based on a literature review</article-title><source>Front Neurol</source><year>2022</year><volume>13</volume><fpage>841310</fpage><pub-id pub-id-type="pmid">35493814</pub-id>
</element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spasic</surname><given-names>S</given-names></name>
<name><surname>Nikolic-Kokic</surname><given-names>A</given-names></name>
<name><surname>Miletic</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Edaravone may prevent ferroptosis in ALS</article-title><source>Curr Drug Targets</source><year>2020</year><volume>21</volume><fpage>776</fpage><lpage>780</lpage><pub-id pub-id-type="pmid">32077821</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hadzhieva</surname><given-names>M</given-names></name>
<name><surname>Kirches</surname><given-names>E</given-names></name>
<name><surname>Wilisch-Neumann</surname><given-names>A</given-names></name>
<etal/></person-group><article-title>Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis</article-title><source>Neuroscience</source><year>2013</year><volume>230</volume><fpage>94</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">23178912</pub-id>
</element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Acosta-Cabronero</surname><given-names>J</given-names></name>
<name><surname>Machts</surname><given-names>J</given-names></name>
<name><surname>Schreiber</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Quantitative susceptibility MRI to detect brain iron in amyotrophic lateral sclerosis</article-title><source>Radiology</source><year>2018</year><volume>289</volume><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">30040038</pub-id>
</element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Halliwell</surname><given-names>B</given-names></name>
<name><surname>Gutteridge</surname><given-names>JMC</given-names></name></person-group><source>Free radicals in biology and medicine</source><edition>3rd</edition><publisher-loc>Oxford</publisher-loc><publisher-name>Oxford University Press</publisher-name><year>1988</year></element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ichikawa</surname><given-names>Y</given-names></name>
<name><surname>Sato</surname><given-names>B</given-names></name>
<name><surname>Hirano</surname><given-names>S</given-names></name>
<name><surname>Takefuji</surname><given-names>Y</given-names></name>
<name><surname>Satoh</surname><given-names>F</given-names></name></person-group><article-title>Realizing brain therapy with &#x0201c;smart medicine&#x0201d;: mechanism and case report of molecular hydrogen inhalation for Parkinson&#x02019;s disease</article-title><source>Med Gas Res</source><year>2024</year><volume>14</volume><fpage>89</fpage><lpage>95</lpage></element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cho</surname><given-names>H</given-names></name>
<name><surname>Shukla</surname><given-names>S</given-names></name></person-group><article-title>Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis</article-title><source>Pharmaceuticals (Basel)</source><year>2020</year><volume>14</volume><fpage>29</fpage><pub-id pub-id-type="pmid">33396271</pub-id>
</element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurokawa</surname><given-names>R</given-names></name>
<name><surname>Hirano</surname><given-names>SI</given-names></name>
<name><surname>Ichikawa</surname><given-names>Y</given-names></name>
<name><surname>Matsuo</surname><given-names>G</given-names></name>
<name><surname>Takefuji</surname><given-names>Y</given-names></name></person-group><article-title>Preventing explosions of hydrogen gas inhalers</article-title><source>Med Gas Res</source><year>2019</year><volume>9</volume><fpage>160</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">31552881</pub-id>
</element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ichikawa</surname><given-names>Y</given-names></name>
<name><surname>Hirano</surname><given-names>SI</given-names></name>
<name><surname>Sato</surname><given-names>B</given-names></name>
<name><surname>Yamamoto</surname><given-names>H</given-names></name>
<name><surname>Takefuji</surname><given-names>Y</given-names></name>
<name><surname>Satoh</surname><given-names>F</given-names></name></person-group><article-title>Guidelines for the selection of hydrogen gas inhalers based on hydrogen explosion accidents</article-title><source>Med Gas Res</source><year>2023</year><volume>13</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">36204781</pub-id>
</element-citation></ref></ref-list></back></article>